Trials with xanthine derivatives in systemic treatment of psoriasis.
Article Details
- CitationCopy to clipboard
Iancu L, Shneur A, Cohen H
Trials with xanthine derivatives in systemic treatment of psoriasis.
Dermatologica. 1979;159(1):55-61.
- PubMed ID
- 225216 [ View in PubMed]
- Abstract
The psoriatic epidermis is more active metabolically and its rate of proliferation is faster, showing incomplete differentiation as a result of the imbalance between the low level of cyclic AMP and the high level of cyclic GMP. The low cyclic AMP levels are due to hyperactivity of the phosphodiesterase which hydrolyzes cyclic AMP. Xanthine derivatives are found to be potent phosphodiesterase inhibitors. 15 psoriatic patients were treated with tablets of xanthine derivatives (dyphylline, aminophylline). The obtained results are discussed.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Dyphylline cAMP-specific 3',5'-cyclic phosphodiesterase 4A Protein Humans YesInhibitorDetails Dyphylline cAMP-specific 3',5'-cyclic phosphodiesterase 4B Protein Humans YesInhibitorDetails Dyphylline cAMP-specific 3',5'-cyclic phosphodiesterase 4C Protein Humans YesInhibitorDetails